Platinum-chemotherapy can enhance the treatment resistance of ovarian cancer cells

Credit: Pixabay/CC0 Public Domain

Researchers from Karolinska Institutet have discovered how platinum chemotherapy can enhance the treatment resistance of ovarian cancer cells, by progressively changing the cancer cell-intrinsic adhesion signaling and cell-surrounding microenvironment.

Platinum chemotherapy is standard treatment in ovarian cancers, but treatment resistance commonly develops. The extracellular matrix (ECM)-derived biochemical and mechanical cues in the are known to contribute to the ability of cancer cells to metastasize and resist treatment. However, how the dynamic communication between the cancer cells and the ECM is affected by, or influences the disease progression and chemotherapy, have remained elusive.

A new study led by Kaisa Lehti, researcher at the Department of Microbiology, Tumor and Cell Biology at KI, and published in Nature Communications, shows that the ECM microenvironment is modulated in metastasis and following chemotherapy. Changes in the ECM proteins variably altered the cell death response of the tumor cells.

"Particularly in the most aggressive solid tumor tissues, cancer cells are surrounded by a prominent fibrotic network of proteins like collagens, known as the (ECM) and also defined as the matrisome when considered with various associated factors including cytokines and chemokines. The ECM/matrisome is produced largely by stromal cells, but sensed and remodeled collectively by the and the cells of the fibrotic tumor stroma. In tumor cells, specific ECM signaling in stiff microenvironment critically increased their resistance against platinum-mediated, apoptosis-inducing DNA damage," Kaisa Lehti explains.

More information: Elina A. Pietilä et al, Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance, Nature Communications (2021). DOI: 10.1038/s41467-021-24009-8

Journal information: Nature Communications
Citation: Platinum-chemotherapy can enhance the treatment resistance of ovarian cancer cells (2021, June 24) retrieved 22 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Therapeutic resistance linked to softer tissue environment in breast cancer


Feedback to editors